Linitis plastica primary prevention

Jump to navigation Jump to search

Linitis plastica Microchapters


Patient Information


Historical Perspective




Differentiating Linitis plastica from Other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


History and Symptoms


Diagnostic study of choice

Physical Examination

Laboratory Findings



Echocardiography and Ultrasound



Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Linitis plastica primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Linitis plastica primary prevention

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Linitis plastica primary prevention

CDC on Linitis plastica primary prevention

Linitis plastica primary prevention in the news

Blogs on Linitis plastica primary prevention

Directions to Hospitals Treating Linitis plastica

Risk calculators and risk factors for Linitis plastica primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]


An effective measure for the primary prevention of hereditary diffuse gastric adenocarcinoma includes prophylactic gastrectomy in individuals who test positive for CDH1 gene mutations.Genetic testing can be carried out in those who have family history of hereditary diffuse gastric adenocarcinoma. The risk for developing gastric cancer is high enough to warrant prophylactic gastrectomy in these patients.

Primary Prevention

Genetic testing

  • CDH1 mutation is detected in 15 - 50 percent of those with hereditary diffuse gastric adenocarcinoma.[1][2][3]
  • The risk of developing diffuse gastric adenocarcinoma in an individual with CDH1 mutation is 70 percent in men and up to 56 percent in women.
  • In 2015, the IGCLC (International Gastric Cancer Linkage Consortium) established criteria for CDH1 mutation testing. A blood or saliva sample is analyzed. Individuals who fall into any of these criteria are candidates for genetic testing:[4]


  1. Pandalai PK, Lauwers GY, Chung DC, Patel D, Yoon SS (2011). "Prophylactic total gastrectomy for individuals with germline CDH1 mutation". Surgery. 149 (3): 347–55. doi:10.1016/j.surg.2010.07.005. PMID 20719348.
  2. Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ, Donohue JH (2001). "Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated?". Cancer. 92 (1): 181–7. PMID 11443625.
  3. Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kurian AW, Ford JM (2007). "CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer". Ann. Surg. 245 (6): 873–9. doi:10.1097/01.sla.0000254370.29893.e4. PMC 1876967. PMID 17522512.
  4. van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, Bardram L, Benusiglio PR, Bisseling TM, Blair V, Bleiker E, Boussioutas A, Cats A, Coit D, DeGregorio L, Figueiredo J, Ford JM, Heijkoop E, Hermens R, Humar B, Kaurah P, Keller G, Lai J, Ligtenberg MJ, O'Donovan M, Oliveira C, Pinheiro H, Ragunath K, Rasenberg E, Richardson S, Roviello F, Schackert H, Seruca R, Taylor A, Ter Huurne A, Tischkowitz M, Joe ST, van Dijck B, van Grieken NC, van Hillegersberg R, van Sandick JW, Vehof R, van Krieken JH, Fitzgerald RC (2015). "Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers". J. Med. Genet. 52 (6): 361–74. doi:10.1136/jmedgenet-2015-103094. PMC 4453626. PMID 25979631.

Template:WikiDoc Sources